米国企業
BIOGEN INC.

BIOGEN INC.BIIB

時価総額

$335.2億

PER

27.5倍

	2010年 12月31日	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Product	-	-	-	-	-	-	-	-	10,887	11,380	10,692	8,847	7,988	7,247
Revenue from anti-CD20 therapeutic programs	-	-	-	-	-	-	-	-	1,980	2,290	1,978	1,659	1,701	-
Revenue from anti-CD20 therapeutic programs	-	-	-	-	-	-	-	-	-	-	-	-	-	1,690
Other	-	-	-	-	-	-	-	-	586	708	775	476	485	-
Contract manufacturing, royalty and other revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	899
Revenues	4,716	5,049	5,516	6,932	9,703	10,764	11,449	12,274	13,453	14,378	13,445	10,982	10,173	9,836
Cost of Goods and Services Sold	400	467	545	858	1,171	1,240	1,479	1,630	1,816	1,955	1,805	2,110	2,278	2,533
Research and development	-	-	-	1,444	1,893	2,013	1,973	2,254	2,597	2,281	3,991	2,501	2,231	2,462
Selling, general and administrative	1,032	1,056	1,277	1,712	2,232	2,113	1,948	1,936	2,106	2,375	2,505	2,674	2,404	2,550
Amortization and impairment of acquired intangible assets	-	-	-	-	-	-	-	-	747	490	465	881	366	241
Collaboration profit sharing	258	318	318	85	-	-	10	112	185	242	233	7	-7	-
Collaboration Profit (Loss) Sharing	-	-	-	-	-	-	-	-	-	-	-	-	-	219
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	-	-	-	-	-	-	-	-	-	55	-92	-	-	-
(Gain) loss on fair value remeasurement of contingent consideration	-	-	-	1	39	-30	-15	-63	12	64	86	51	209	-
(Gain) loss on fair value remeasurement of contingent consideration	-	-	-	1	39	-30	-15	-63	12	64	86	51	209	-
Acquired in-process research and development	245	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and Development in Process	271	-	-	-	-	-	-	120	113	-	75	18	-	-
Restructuring charges	75	19	2	-	-	93	33	1	12	2	-	-	131	219
Restructuring charges	75	19	2	-	-	93	33	1	12	2	-	-	131	219
Gain on sale of building	-	-	-	-	-	-	-	-	-	-	-	-	504	-
Gain on sale of building	-	-	-	-	-	-	-	-	-	-	-	-	504	-
Other (income) expense, net	-	-	-	-	-	-	-	-215	11	83	497	-1,095	108	-315
Other (income) expense, net	-	-	-	-	-	-	-	-215	11	83	497	-1,095	108	-315
Total cost and expense	3,468	3,324	3,707	4,442	5,748	5,873	6,298	6,930	7,564	7,335	8,895	8,141	6,582	8,539
Total cost and expense	3,468	3,324	3,707	4,442	5,748	5,873	6,298	6,930	7,564	7,335	8,895	8,141	6,582	8,539
Income before income tax (benefit) expense and equity in loss of investee, net of tax	1,230	1,711	1,855	2,481	3,947	4,767	4,933	5,129	5,900	7,126	5,048	1,745	3,592	1,297
Income tax (benefit) expense	331	445	471	601	990	1,162	1,237	2,459	1,426	1,158	992	53	633	135
Equity in (income) loss of investee, net of tax	-	-	-	-	-	-	-	-	-	-	5	35	3	-
Net income	899	1,267	1,380	1,862	2,942	3,593	3,696	2,670	4,474	5,889	4,061	1,728	2,962	1,162
Net Income (Loss) Attributable to Noncontrolling Interest	-107	32	-	-	7	46	-7	131	43	-	60	172	-85	0
Net income attributable to Biogen Inc.	1,005	1,267	1,380	1,862	2,942	3,593	3,703	2,670	4,474	5,889	4,061	1,728	3,047	1,162
Earnings Per Share, Basic	3.98	5.09	5.8	7.86	12.42	15.38	16.96	11.94	21.63	31.47	24.86	10.44	20.96	8.02
Earnings Per Share, Diluted	3.94	5.04	5.76	7.81	12.37	15.34	16.93	11.92	21.58	31.42	24.8	10.4	20.87	7.97